Wiener Medizinische Wochenschrift

, Volume 159, Issue 1–2, pp 17–23 | Cite as

Vareniclin – medikamentöse Therapie der Tabakabhängigkeit

  • Patricia Tschabitscher
  • Irmgard Homaier
  • Alfred Lichtenschopf
  • Ernest Groman


Jedes Jahr gibt es in Europa 1,2 Millionen Todesfälle, die auf Zigarettenkonsum zurückzuführen sind. Effektive Raucherentwöhnung ist daher von besonderer Bedeutung. Vareniclin ist das erste Medikament, das speziell zur Raucherentwöhnung neu entwickelt wurde. Die Wirksamkeit von Vareniclin bei der Raucherentwöhnung beruht auf seiner Wirkung als partieller Agonist/Antagonist am α4β2-Nikotinrezeptor. Dieser duale Wirkmechanismus bewirkt einerseits eine Verminderung des Rauchverlangens sowie eine Linderung der Entzugssymptome und hemmt andererseits die direkte Wirkung des Rauchens. Dieser Artikel diskutiert die derzeitigen Studiendaten zur Sicherheit und Effektivität von Vareniclin und dessen Bedeutung in der Raucherentwöhnung.


Vareniclin Raucherentwöhnung Nikotinabgängigkeit 

Varenicline – pharmacological therapy of tobacco dependence


Every year about 1.2 million deaths attributable to smoking occur in Europe. Effective smoking cessation, therefore, is essential. Varenicline is the first medication specifically developed for smoking cessation. The efficacy of varenicline in smoking cessation is due to its role as a partial agonist/antagonist at the α4β2 nicotine receptors. This dual action causes a reduction in cigarette craving as well as withdrawal symptoms; moreover, it decreases the pleasurable and reinforcing effects of smoking. This article discusses the current clinical data regarding efficacy and safety of varenicline and its role in smoking cessation.

Key words

Varenicline Smoking cessation Nicotine dependence 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. World Health Organization ICD-10 Classification of Mental and Behavioural Disorders: F17.2 Tobacco Dependence SyndromeGoogle Scholar
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). American Psychiatric Association, Arlington, VA, 2000Google Scholar
  3. Fiore MC, Bailey WC, Cohen SJ, et al. Clinical practice guideline. Treating tobacco use and dependence. Rockville, MD, US Department of Health and Human, 2000Google Scholar
  4. Boyle P, Gandini S, Robertson C, et al. Characteristics of smokers' attitudes towards stopping: Survey of 10295 smokers in representative samples from 17 European countries. Eur J Public Health, 10(3 Suppl): 5–14, 2000CrossRefGoogle Scholar
  5. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction, 99: 29–38, 2004PubMedCrossRefGoogle Scholar
  6. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem, 48: 3474–3477, 2005PubMedCrossRefGoogle Scholar
  7. Olale F, Gerzanich V, Kuryatov A, et al. Chronic nicotine exposure differentially affects the function of human alpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther, 283: 675–683, 1997PubMedGoogle Scholar
  8. Dani JA, De Biasi M. Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav, 70: 439–446, 2001PubMedCrossRefGoogle Scholar
  9. Faessel HM, Smith BJ, Gibbs MA, et al. Single-dosepharmacokinetics of Varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol, 46: 991–998, 2006PubMedCrossRefGoogle Scholar
  10. Champix® Fachinformation, Stand April 2007Google Scholar
  11. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of Varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos, 34: 121–130, 2006PubMedCrossRefGoogle Scholar
  12. Faessel H, Burstein A, O'Gorman M, et al. Safety, tolerability of varenicline and digoxin or warfarin [abstract]. 11th Annual Meeting and 7th European Conference of the Society for Research on Nicotine and Tobacco, Mar 16–20; Prague, 2005Google Scholar
  13. Gonzales D, Rennard SI, Nides M, et al. Varenicline Phase 3 Study Group. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA, 296: 47–55, 2006PubMedCrossRefGoogle Scholar
  14. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA, 296: 56–63, 2006PubMedCrossRefGoogle Scholar
  15. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with Varenicline on smoking cessation: a randomized controlled trial. JAMA, 296: 64–71, 2006PubMedCrossRefGoogle Scholar
  16. Williams KE, Reeves KR, Billing CB Jr, et al. A double-blind study evaluating the long-term safety of Varenicline for smoking cessation. Curr Med Res Opin, 23: 793–801, 2007PubMedCrossRefGoogle Scholar
  17. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, Varenicline, for smoking cessation. Arch Intern Med, 166: 1571–1577, 2006PubMedCrossRefGoogle Scholar
  18. FDA ALERT [2/1/2008]: accessed on 01.03.2008
  19. EMEA Press release: European medicines agency concludes new advice to doctors and patients for Champix needed accessed on 11.03.2008
  20. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction, 103: 146–154, 2007PubMedCrossRefGoogle Scholar
  21. Hughes JR. New treatments for smoking cessation. CA Cancer J Clin, 50: 143–151, 2000PubMedCrossRefGoogle Scholar
  22. Coleman T. ABC of smoking cessation. Use of simple advice and behavioural support. BMJ, 328: 397–399, 2004PubMedCrossRefGoogle Scholar
  23. The European Health Report. WHO regional publications, European series; No. 97, Copenhagen, 2002Google Scholar
  24. Centers for disease control and prevention: Annual smoking-attributable mortality, years of potential life lost, and productivity losses – United States, 1997–2001Google Scholar
  25. Rutten-van Molken M, et al. Cost-effectiveness of Varenicline for smoking cessation in five European countries. Proceedings of the 9th European SNRT Conference, Oct 3–6; Madrid, Spain, 2007Google Scholar
  26. Minami J, Ishimitsu T, Matsuoka H. Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers. Hypertension, 33: 586–590, 1999PubMedGoogle Scholar
  27. Schroeder SA. What to do with a patient who smokes. JAMA, 294: 482–487, 2005PubMedCrossRefGoogle Scholar
  28. Centers for Disease Control and Prevention. The surgeon general's, report on the health benefits of smoking cessation executive summary – preface. MMWR Morb Mortal Wkly Rep, 39(RR-12): viii–xv, 1990Google Scholar
  29. Cromwell J, Bartosch WJ, Fiore MC, et al. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA, 278: 1759–1766, 1997PubMedCrossRefGoogle Scholar
  30. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of systematic reviews 2008, issue 3. Art. No. CD006103Google Scholar
  31. Varenicline for smoking cessation, NICE technology appraisal guidance 123; July 2007Google Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Patricia Tschabitscher
    • 1
  • Irmgard Homaier
    • 2
  • Alfred Lichtenschopf
    • 3
  • Ernest Groman
    • 4
  1. 1.Pfizer Corporation AustriaWienAustria
  2. 2.Pulmogisches Zentrum WienBaumgartner HöheWienAustria
  3. 3.Sonderkrankenanstalten SKA-RZ WeyerWeyerAustria
  4. 4.Institut für Sozialmedizin, Zentrum für Public HealthMedizinische Universität Wien und Nikotin InstitutWienAustria

Personalised recommendations